While taking the drug, all 12 patients showed improvement in sleep scores commonly used in people with obstructive sleep apnea. They experienced half as many slowed or stopped breathing episodes during sleep, and there was a 28% reduction in the overall number of sleep disruptions.
The research was funded by Remeron manufacturer Organon, Inc., and presented in Chicago this week at the annual meeting of the Associated Professional Sleep Societies.
First Potential Drug Treatment
"We have been testing drug candidates for this disorder for well over 20 years, but this is the first time that a drug has shown a benefit of this size and consistency in sleep apnea patients," study researcher David W. Carley, PhD, tells WebMD.
More than 12 million Americans are believed to suffer from obstructive sleep apnea, although most have not been diagnosed. People with the condition may stop breathing hundreds of times a night, often for a minute or more. Loud snoring and daytime sleepiness are the most common symptoms, but sleep apnea can also lead to high blood pressure, heart disease, and stroke.
Obstructive sleep apnea is caused by the blockage of airflow from the nose to the mouth during sleep. The most common treatment for the condition is a machine that forces air into the nose to maintain an open airway passage and allow normal breathing to maintain oxygen levels. Known as continuous positive air pressure, or CPAP, the therapy is very effective, but many patients find sleeping in a mask or nasal prongs uncomfortable.
"(CPAP) definitely works, but it is inconvenient and hard to tolerate," Carley says. "Some patients won't even attempt it, and many more who do quickly give up."
Fewer Sleep Disturbances
The 12 obstructive sleep apnea patients in the study were treated with either high or low doses of Remeron or a placebo an hour before bedtime. They were then monitored throughout the night at a University of Illinois at Chicago sleep center after each of three seven-day treatment periods.